CH630806A5 - Method for preparing improved vaccines - Google Patents
Method for preparing improved vaccines Download PDFInfo
- Publication number
- CH630806A5 CH630806A5 CH469078A CH469078A CH630806A5 CH 630806 A5 CH630806 A5 CH 630806A5 CH 469078 A CH469078 A CH 469078A CH 469078 A CH469078 A CH 469078A CH 630806 A5 CH630806 A5 CH 630806A5
- Authority
- CH
- Switzerland
- Prior art keywords
- ribosomes
- rna
- vaccine
- capsular polysaccharides
- pneumoniae
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 33
- 238000000034 method Methods 0.000 title claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 55
- 229920001282 polysaccharide Polymers 0.000 claims description 55
- 239000005017 polysaccharide Substances 0.000 claims description 55
- 210000003705 ribosome Anatomy 0.000 claims description 38
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 241000606768 Haemophilus influenzae Species 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 7
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 2
- 229960004830 cetylpyridinium Drugs 0.000 claims 1
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical group CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 229920002477 rna polymer Polymers 0.000 description 24
- 238000005119 centrifugation Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 11
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 235000017281 sodium acetate Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 108020004418 ribosomal RNA Proteins 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 235000015842 Hesperis Nutrition 0.000 description 1
- 235000012633 Iberis amara Nutrition 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- -1 disodium salt Chemical class 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7713009A FR2388563A1 (fr) | 1977-04-29 | 1977-04-29 | Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH630806A5 true CH630806A5 (en) | 1982-07-15 |
Family
ID=9190107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH469078A CH630806A5 (en) | 1977-04-29 | 1978-04-28 | Method for preparing improved vaccines |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS53136516A (enExample) |
| BE (1) | BE866464A (enExample) |
| CA (1) | CA1103155A (enExample) |
| CH (1) | CH630806A5 (enExample) |
| DE (1) | DE2818922A1 (enExample) |
| ES (1) | ES469225A1 (enExample) |
| FR (1) | FR2388563A1 (enExample) |
| GB (1) | GB1603340A (enExample) |
| IT (1) | IT1156717B (enExample) |
| NL (1) | NL7804660A (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1115210A (en) * | 1977-11-28 | 1981-12-29 | Dennis J. Carlo | Pneumococcal vaccine |
| US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
| FR2444464A1 (fr) * | 1978-12-19 | 1980-07-18 | Fabre Sa Pierre | Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| US4287173A (en) * | 1979-09-24 | 1981-09-01 | Merck & Co., Inc. | Vaccine for dental caries |
| FR2471785A1 (fr) * | 1979-12-21 | 1981-06-26 | Fabre Sa Pierre | Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn |
| FR2475900A1 (fr) * | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
| FR2495939B1 (fr) * | 1980-12-11 | 1985-10-11 | Merieux Inst | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| BE889979A (fr) * | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| GB8906795D0 (en) * | 1989-03-23 | 1989-05-10 | Carroll Noel | Method of preparing vaccines |
| DE4141970C2 (de) * | 1991-12-16 | 1998-02-19 | Charite Med Fakultaet | Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung |
| JPH0651347U (ja) * | 1992-12-21 | 1994-07-12 | 有限会社河上建築事務所 | 軒樋の枯葉止め |
| FR2703252B1 (fr) * | 1993-03-31 | 1996-09-06 | Fernand Narbey Torossian | Complexe immunomodulateur anti SIDA. |
| US6410025B1 (en) | 1996-02-14 | 2002-06-25 | Merck & Co., Inc. | Polysaccharide precipitation process |
| CA2245588C (en) * | 1996-02-14 | 2006-05-09 | Russel J. Lander | Polysaccharide precipitation process |
| FR2790961B1 (fr) * | 1999-03-17 | 2001-06-22 | Fabre Pierre Sante | Utilisation d'une composition comprenant des proteoglycanes de klebsiella pneumoniae, et des ribosomes ou des arn ribosomaux bacteriens pour le traitement et/ou la prevention des maladies parodontales |
-
1977
- 1977-04-29 FR FR7713009A patent/FR2388563A1/fr active Granted
-
1978
- 1978-04-27 ES ES469225A patent/ES469225A1/es not_active Expired
- 1978-04-27 BE BE187182A patent/BE866464A/xx not_active IP Right Cessation
- 1978-04-28 CA CA302,203A patent/CA1103155A/fr not_active Expired
- 1978-04-28 IT IT49126/78A patent/IT1156717B/it active
- 1978-04-28 DE DE19782818922 patent/DE2818922A1/de not_active Withdrawn
- 1978-04-28 NL NL7804660A patent/NL7804660A/xx not_active Application Discontinuation
- 1978-04-28 CH CH469078A patent/CH630806A5/fr not_active IP Right Cessation
- 1978-04-28 GB GB16933/78A patent/GB1603340A/en not_active Expired
- 1978-05-01 JP JP5262378A patent/JPS53136516A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2388563B1 (enExample) | 1981-01-09 |
| GB1603340A (en) | 1981-11-25 |
| IT1156717B (it) | 1987-02-04 |
| BE866464A (fr) | 1978-10-27 |
| CA1103155A (fr) | 1981-06-16 |
| DE2818922A1 (de) | 1978-11-09 |
| IT7849126A0 (it) | 1978-04-28 |
| ES469225A1 (es) | 1978-11-16 |
| NL7804660A (nl) | 1978-10-31 |
| FR2388563A1 (fr) | 1978-11-24 |
| JPS53136516A (en) | 1978-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH630806A5 (en) | Method for preparing improved vaccines | |
| EP0024493B1 (en) | Multivalent pneumococcal vaccine | |
| US4271147A (en) | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same | |
| EP0157899A2 (en) | Multivalent pneumococcal vaccine and preparation thereof | |
| FR2475900A1 (fr) | Complexe vaccinal contenant un antigene specifique et vaccin le contenant | |
| CN103266152B (zh) | 一种利用固定化海藻糖合成酶生产海藻糖的方法 | |
| EP0013851A1 (fr) | Protéoglycanes bactériens purifiés, procédé pour leur préparation et vaccin les contenant | |
| Duff et al. | STUDIES ON IMMUNITY TO TOXINS OF CLOSTRIDIUM BOTULINUM II: Production and Purification of Type B Toxin for Toxoid | |
| EP0031285B1 (fr) | Préparations immunostimulantes à base d'ARN ribosomaux de Klebsiella pneumoniae et procédé de préparation de ces ARN | |
| EP0179679B1 (fr) | Polysaccharides membranaires utiles notamment comme médicament et procédé pour leur préparation | |
| JPH0834742B2 (ja) | 百日せき内毒素の除去法，百日せきトキソイドおよびその製造法 | |
| EP0238407B1 (fr) | Procédés industriels de fabrication de vaccins ribosomaux et vaccins ribosomaux obtenus | |
| FR2523154A1 (fr) | Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant | |
| CH662056A5 (fr) | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies. | |
| RU2051969C1 (ru) | Способ получения бактериальных липополисахаридов | |
| Henrikson et al. | Fatty acid composition, distribution, and requirements of two nonsterol-requiring mycoplasmas from complex but defatted growth media | |
| RU2704452C1 (ru) | Способ получения вакцины гемофильной тип b конъюгированной | |
| EP0390624B1 (fr) | Procédé microbiologique d'obtention de méthylcétones | |
| CN106011108B (zh) | 一种利用槐糖脂衍生物共价修饰的溶菌酶及其修饰方法和应用 | |
| FR2462166A1 (fr) | Compositions antigeniques, leur preparation et vaccins a base de ces compositions | |
| FR2536280A1 (fr) | Composition pharmaceutique et procede pour le traitement de tumeurs | |
| FR2602681A1 (fr) | Procede de preparation d'un vaccin recombinant contre l'hepatite b | |
| JP2926254B2 (ja) | 天然ジャスミン酸の製造法 | |
| CH423098A (fr) | Procédé de préparation d'un vaccin staphylococcique | |
| CA1187793A (en) | Vaccine and method of making |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: P.F. MEDICAMENT |
|
| PL | Patent ceased |